SCHEMBL25242597

SCHEMBL25242597

Cc1c(O)ccc(C(=O)c2ccc(F)cc2)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
ALDH1A1 P00352 3/20 0.56
NPC1 O15118 1/20 0.56
HTT P42858 1/20 0.56
RAB9A P51151 1/20 0.56
HSD17B10 Q99714 4/20 0.47
MAPT P10636 3/20 0.45
KDM4E B2RXH2 2/20 0.45
HPGD P15428 2/20 0.45
RECQL P46063 2/20 0.45
ALOX15 P16050 2/20 0.45
HDAC1 Q13547 1/20 0.43
KCNMA1 Q12791 1/20 0.42
LTA4H P09960 1/20 0.42
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TTR P02766 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11211367 0.86 MAPT (0.56) KMT2AMEN1ALDH1A1NPC1HTT
SCHEMBL29215682 0.86 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1NPC1HTT
SCHEMBL8486479 0.84 HDAC1 (0.61) KMT2AMEN1ALDH1A1HSD17B10MAPT
SCHEMBL16993472 0.83 HDAC1 (0.49) KMT2AMEN1ALDH1A1NPC1HTT
SCHEMBL30331291 0.82 MAPT (0.56) KMT2AMEN1ALDH1A1HTTHSD17B10
SCHEMBL2859239 0.82 MAPT (0.56) KMT2AMEN1ALDH1A1HTTHSD17B10
SCHEMBL18241788 0.81 HDAC1 (0.54) KMT2AMEN1ALDH1A1NPC1HTT
SCHEMBL1758260 0.81 KMT2A (0.51) KMT2AMEN1ALDH1A1NPC1HTT
SCHEMBL11218165 0.80 NPC1 (0.55) KMT2AMEN1ALDH1A1NPC1HTT
SCHEMBL25251755 0.80 SIRT1 (0.57) KMT2AMEN1ALDH1A1NPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179000-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-06-05 US disclosed
EP-4452918-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2024-10-30 EP disclosed
WO-2023122276-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179000-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF GRM3, GRM2, GRM1 KMT2A 944/4885MEN1 3296/4885ALDH1A1 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.